Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jun 28, 2009; 15(24): 3032-3037
Published online Jun 28, 2009. doi: 10.3748/wjg.15.3032
Published online Jun 28, 2009. doi: 10.3748/wjg.15.3032
Table 2 Baseline characteristics of the study groups (%)
| Characteristics | Simethicone | Placebo |
| n= 62 | n= 60 | |
| Age (yr); mean (SD) | 57.5 (9.9) | 56.5 (11.7) |
| Gender | ||
| Male | 27 (43.5) | 23 (37.1) |
| Female | 35 (56.6) | 37 (61.7) |
| Indication for colonoscopy | ||
| Screening | 25 (40.3) | 26 (43.3) |
| Symptomatic | 37 (59.7) | 34 (56.7) |
| Underlying diseases | ||
| Diabetic | 14 (22.6) | 12 (20.0) |
| Hypertension | 17 (27.4) | 16 (26.7) |
| Coronary artery disease | 2 (3.2) | 3 (5.0) |
| Liver disease | 10 (16.1) | 5 (8.3) |
| Malignancy | 5 (8.1) | 8 (13.3) |
| GI disease | 7 (11.3) | 3 (5.0) |
| No underlying disease | 18 (29.0) | 22 (36.7) |
| Medication | ||
| Antihypertensive agent | 19 (30.7) | 20 (33.3) |
| Hypoglycemic agent | 12 (19.4) | 11 (18.3) |
| Antiplatelet | 4 (6.5) | 7 (11.7) |
| No medication | 25 (40.3) | 27 (45.0) |
- Citation: Tongprasert S, Sobhonslidsuk A, Rattanasiri S. Improving quality of colonoscopy by adding simethicone to sodium phosphate bowel preparation. World J Gastroenterol 2009; 15(24): 3032-3037
- URL: https://www.wjgnet.com/1007-9327/full/v15/i24/3032.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3032